|
NCT04374461
|
A Study of N-acetylcysteine in Patients With COVID-19 Infection |
Active, not recruiting |
Phase 2 |
May/01/2020 |
May/01/2023 |
- Alternative id - 20-168
- Interventions - Drug: N-acetylcysteine|Other: Peripheral Blood
- Study type - Interventional
- Study results - No Results Available
- Locations - Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 48
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Arm A: number of patients who are successfully extubated and/or transferred out of critical care due to clinical improvement|Arm B: number of patients who are discharged from the hospital due to clinical improvement
|
|
NCT04792021
|
Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients |
Recruiting |
Phase 3 |
Mar/09/2021 |
Nov/01/2021 |
- Alternative id - N-acetylcysteine in COVID 19
- Interventions - Drug: N-acetylcysteine
- Study type - Interventional
- Study results - No Results Available
- Locations - Al Assema Hospital, Cairo, Egypt
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
- Enrollment - 60
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Change in TNF alfa level from baseline|Change in IL-6 level from baseline|Change in glutathione peroxidase level from baseline|Length of hospital stay|Need for mechanical ventilation
|
|
NCT04755972
|
Mucolytics in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2 |
Completed |
Not Applicable |
Oct/01/2020 |
Jul/29/2021 |
- Alternative id - 2181-147-01/06/M.S.-20-02
- Interventions - Other: Inhalation of N-acetylcysteine|Other: Inhalation of 5% sodium chloride|Other: Inhalation of 8,4% sodium bicarbonate
- Study type - Interventional
- Study results - No Results Available
- Locations - Clinical Hospital Centre Split, Split, Croatia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
- Enrollment - 175
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Difference between 4 arms regarding ventilator-associated pneumonia rate|Number of ventilator-free days|Mortality
|
|
NCT05074121
|
NAC for Attenuation of COVID-19 Symptomatology |
Not yet recruiting |
Phase 2 |
Mar/31/2022 |
Feb/01/2023 |
- Alternative id -
- Interventions - Drug: N-acetylcysteine|Other: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - Cambridge Health Alliance, Everett, Massachusetts, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
- Enrollment - 200
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Symptom severity|Symptom duration|Need for higher level of care/hospitalization
|
|
NCT04703036
|
Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19 |
Recruiting |
Early Phase 1 |
Jan/11/2021 |
Dec/31/2023 |
- Alternative id - H48057
- Interventions - Dietary Supplement: Glycine|Dietary Supplement: N-acetylcysteine|Dietary Supplement: Alanine
- Study type - Interventional
- Study results - No Results Available
- Locations - Baylor College of Medicine, Houston, Texas, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other
- Enrollment - 64
- Age - 55 Years to 85 Years (Adult, Older Adult)
- Outcome measures - Change in Glutathione concentrations|Change in Interleukein 6 concentrations|Change in Ordinal scale|Change in oxidative stress|Change in marker of damage due to oxidative stress|Change in inflammatory cytokines|Change in mitochondrial energetics|Change in immune function|Change in cognition|Change in function|Change in fatigue|Change in circulating marker of memory
|
|
NCT04928495
|
Clinical Trial With N-acetylcysteine and Bromhexine for COVID-19 |
Not yet recruiting |
Phase 3 |
Jul/15/2021 |
Jun/09/2022 |
- Alternative id - AVANTI-C19
- Interventions - Drug: Vitamin C|Drug: N-acetylcysteine (NAC)|Drug: NAC + Bromhexine (BMX)
- Study type - Interventional
- Study results - No Results Available
- Locations - Núcleo de Biomedicina - NUBIMED, Fortaleza, Ceará, Brazil
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 219
- Age - 18 Years to 60 Years (Adult)
- Outcome measures - The time to recovery, defined at day 7 days follow up after enrollment, on which a patient met the criteria for category 1 or 2 on the four-category ordinal scale. [Time Frame: Day 7 follow up after enrollment.]|SARS-CoV-2 RNA viral load measurements change. [ Time Frame: Change between Day 1 and Day 7 follow up after enrollment. ]|Proportion of patients with qualitative serum IgM / IgG. [ Time Frame: Proportion of positive patients at Day 7 for IgM / IgG (N; %). ]|Biomarkers (IL-6, MCP-3, D-dimer, IL1-RA, IL-10, GCSF, TNF-α, MCP-1, IL-2R, MIP-1 alpha, IP-10, IL-8, NT-proBNP, Troponin I, CRP and procalcitonin) measurements change. [ Time Frame: Change between Day 1 and Day 14 follow up after enrollment. ]
|
|
NCT05258682
|
Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease |
Not yet recruiting |
Phase 1|Phase 2 |
May/01/2022 |
Oct/30/2022 |
- Alternative id - MUC-COV-003
- Interventions - Drug: Bromelains|Drug: Acetylcysteine
- Study type - Interventional
- Study results - No Results Available
- Locations -
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 30
- Age - 18 Years to 75 Years (Adult, Older Adult)
- Outcome measures - Evaluate the treatment-emergent adverse events (AEs) of BromAc therapy following nebulised delivery|Proportion of participants that proceed to invasive ventilation for deterioration of COVID-19 (need for mechanical ventilation)|World Health Organisation (WHO) modified ordinal scale clinical score|Improvement or deterioration in oxygenation|All-cause mortality|Dose related toxicities|Treatment-emergent serious adverse events (SAEs)
|
|
NCT04419025
|
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease |
Completed |
Phase 2 |
Sep/23/2020 |
May/14/2021 |
- Alternative id - CHA-IRB-1139/05/20
- Interventions - Drug: N-acetylcysteine
- Study type - Interventional
- Study results - No Results Available
- Locations - CHA Cambridge Hospital, Cambridge, Massachusetts, United States|CHA Everett Hospital, Everett, Massachusetts, United States|CHA Respiratory Clinic, Somerville, Massachusetts, United States|CHA Somerville campus, Somerville, Massachusetts, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 165
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Decrease in Respiratory Rate|Hospital length of stay (LOS)|Need for mechanical ventilation|Length of time intubated|Need for hospitalization|Recovery disposition
|
